Literature DB >> 4057189

Comparison of hydroxychloroquine and chloroquine use and the development of retinal toxicity.

D S Finbloom, K Silver, D A Newsome, R Gunkel.   

Abstract

We assessed the frequency of retinal toxicity in patients receiving either chloroquine or hydroxychloroquine and factors which may predict patient susceptibility to toxicity. The overall frequency of retinopathy was 6% (7 of 110 patients). Of the 31 patients receiving chloroquine alone, 6 developed toxicity (19%). In contrast, of the 66 patients receiving hydroxychloroquine, none developed retinopathy. Retinopathy was associated with greater age and with greater accumulative doses of chloroquine. Thus, hydroxychloroquine can be used safely with minimal risk of toxicity.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4057189

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  38 in total

Review 1.  Recognition and management of systemic lupus erythematosus.

Authors:  J O Schroeder; H H Euler
Journal:  Drugs       Date:  1997-09       Impact factor: 9.546

Review 2.  The role of antimalarial agents in the treatment of SLE and lupus nephritis.

Authors:  Senq-J Lee; Earl Silverman; Joanne M Bargman
Journal:  Nat Rev Nephrol       Date:  2011-10-18       Impact factor: 28.314

3.  Visual field and multifocal electroretinography and their correlations in patients on hydroxychloroquine therapy.

Authors:  Timothy Y Y Lai; Jasmine W S Ngai; Wai-Man Chan; Dennis S C Lam
Journal:  Doc Ophthalmol       Date:  2006-06-28       Impact factor: 2.379

4.  Long-term effectiveness of antimalarial drugs in rheumatic diseases.

Authors:  J A Aviña-Zubieta; G Galindo-Rodriguez; S Newman; M E Suarez-Almazor; A S Russell
Journal:  Ann Rheum Dis       Date:  1998-10       Impact factor: 19.103

Review 5.  Therapeutic options for cutaneous lupus erythematosus: recent advances and future prospects.

Authors:  Joshua Chang; Victoria P Werth
Journal:  Expert Rev Clin Immunol       Date:  2016-06-01       Impact factor: 4.473

6.  Hydroxychloroquine sulphate in the treatment of rheumatoid arthritis: a double blind comparison of two dose regimens.

Authors:  K Pavelka; K P Sen; Z Pelísková; J Vácha; K Trnavský
Journal:  Ann Rheum Dis       Date:  1989-07       Impact factor: 19.103

Review 7.  Treatment of lupus nephritis.

Authors:  Fayez F Hejaili; Louise M Moist; William F Clark
Journal:  Drugs       Date:  2003       Impact factor: 9.546

8.  Curvilinear bodies are associated with adverse effects on muscle function but not with hydroxychloroquine dosing.

Authors:  Thomas Khoo; Sophia Otto; Caroline Smith; Barbara Koszyca; Sue Lester; Peter Blumbergs; Vidya Limaye
Journal:  Clin Rheumatol       Date:  2016-09-14       Impact factor: 2.980

9.  Hydroxychloroquine retinopathy screening.

Authors:  A E Semmer; M S Lee; A R Harrison; T W Olsen
Journal:  Br J Ophthalmol       Date:  2008-10-01       Impact factor: 4.638

10.  Improving the risk-benefit relationship and informed consent for patients treated with hydroxychloroquine.

Authors:  Allan J Flach
Journal:  Trans Am Ophthalmol Soc       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.